Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review

We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978
Source: Allergologia et Immunopathologia - Category: Allergy & Immunology Authors: Source Type: research